Pepgen Inc (PEPG)

$4.74 -0.15 (-3.07%)
Market Cap 168.26M
Revenue (ttm) 0.00
Net Income (ttm) -89.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 338,100
Avg Vol 4,260,698
Day's Range N/A - N/A
Shares Out 32.80M
Stochastic %K 73%
Beta 1.95
Analysts Strong Sell
Price Target $9.50

Company Profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 797 0979
Website: pepgen.com
Address:
321 Harrison Avenue, 8th Floor, Boston, United States
Stockman824
Stockman824 Nov. 14 at 3:40 PM
$PEPG why won’t my Schwab account allow me to buy PEPG? It’s said I have to call Schwab? Is this a temporary thing? Thanks
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 5:43 PM
HC Wainwright & Co. has adjusted their stance on PepGen ( $PEPG ), setting the rating to Buy with a target price of 18 → 20.
0 · Reply
d_risk
d_risk Nov. 12 at 4:36 PM
$PEPG - PepGen Inc. Common Stock - 10Q - Updated Risk Factors PEPG’s risk factors now detail ongoing losses, a strategic pivot to PGN-EDODM1, and winding down DMD R&D, with high funding needs and persistent going concern doubts. Expanded disclosures highlight clinical trial, regulatory, and commercialization hurdles, new risks from social media, patient enrollment, and third-party reliance, plus heightened exposure to litigation, compliance, cybersecurity, and tax uncertainties. IP risks are streamlined but emphasize patent validity and competition. Recent capital raise noted, but volatility, insider control, and no dividends remain key investor risks. #Biotechnology #IntellectualProperty #FundingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/PEPG/10-Q/2025-11-12
0 · Reply
PiratesKingLuffy
PiratesKingLuffy Nov. 12 at 3:10 AM
AMZE Expecting a big move here tomorrow. Very bullish close today!! AMZE has extended its partnership with Adobe Express, expanding platform access to creators in India — a market with over 2 million monetized creators and $350B in consumer spending. The integration lets users design and sell custom merchandise directly on Amaze, streamlining the path from creation to commerce. The expansion follows Amaze’s showcase at Adobe MAX 2025. Lets bank on AMZE such a gem here! $FGL $FIGS $RLMD $PEPG ..1
2 · Reply
RadioIsotope25
RadioIsotope25 Nov. 9 at 2:39 PM
$RADX Jones Trading reaffirms $30 target after the radiopharmaceutical leader - Lantheus invests more ahead of high potential clinical pipeline updates across imaging and radionuclide lutetium therapeutics utilizing same warheads as the blockbuster Pluvicto and Lutathera. $QURE $PEPG $ATNF $RANI
0 · Reply
Daamdoom1711
Daamdoom1711 Oct. 29 at 1:49 PM
$PEPG P O S
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 27 at 6:57 PM
What do $PEPG $IFRX $EYPT have in common? All are owned by Suvretta, Adage, and RA Capital. All have done secondary offering in last several months PEPG at $3.30 and EYPT at $12.50 (both offering last 2 months). All had major short interest increase just prior to offering. PEPG short grew 359% 9.9% float EYPT up 275% current 14% float IFRX up 113% 3% float* $IFRX data due in 0-7 days *They are about to run the play again.
1 · Reply
notreload_ai
notreload_ai Oct. 27 at 3:53 PM
$PEPG , $DYN
0 · Reply
Davidwxyz
Davidwxyz Oct. 27 at 2:14 PM
$PEPG moving up to 7 or 8
2 · Reply
Lowlow1
Lowlow1 Oct. 27 at 12:43 PM
$PEPG ydkg is going to pop at its 52 low rising looking good,.,....just take a look.,...,...,...........hurry upz...
0 · Reply
Latest News on PEPG
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

Nov 12, 2025, 7:05 AM EST - 2 days ago

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 7:00 AM EST - 2 days ago

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 11 days ago

PepGen to Participate in Upcoming Investor Conferences

PepGen: DMD Discontinued, Ways To Go With DM1

Oct 7, 2025, 6:38 PM EDT - 5 weeks ago

PepGen: DMD Discontinued, Ways To Go With DM1

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

Oct 2, 2025, 7:00 AM EDT - 6 weeks ago

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Sep 26, 2025, 4:01 PM EDT - 7 weeks ago

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

Sep 25, 2025, 9:46 AM EDT - 7 weeks ago

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

PepGen Announces Pricing of $100 Million Public Offering

Sep 24, 2025, 10:51 PM EDT - 7 weeks ago

PepGen Announces Pricing of $100 Million Public Offering

PepGen Announces Proposed Public Offering

Sep 24, 2025, 4:21 PM EDT - 7 weeks ago

PepGen Announces Proposed Public Offering

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

Sep 24, 2025, 4:16 PM EDT - 7 weeks ago

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 3 months ago

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 30, 2025, 5:41 PM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 29, 2025, 10:33 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 23, 2025, 11:22 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

Jun 23, 2025, 9:00 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

Jun 16, 2025, 10:39 AM EDT - 5 months ago

Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 10, 2025, 10:44 AM EDT - 5 months ago

PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

May 29, 2025, 9:19 AM EDT - 6 months ago

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

PepGen to discontinue development of experimental Duchenne therapy; shares drop

May 28, 2025, 6:21 PM EDT - 6 months ago

PepGen to discontinue development of experimental Duchenne therapy; shares drop

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

May 28, 2025, 4:05 PM EDT - 6 months ago

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 6 months ago

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 8, 2025, 8:00 AM EDT - 6 months ago

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 8 months ago

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

PepGen Announces Appointment of Two New Directors to its Board

Mar 31, 2025, 4:05 PM EDT - 8 months ago

PepGen Announces Appointment of Two New Directors to its Board

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Mar 10, 2025, 4:05 PM EDT - 8 months ago

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls

Mar 4, 2025, 1:41 PM EST - 9 months ago

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

Mar 4, 2025, 8:00 AM EST - 9 months ago

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

Feb 24, 2025, 7:30 AM EST - 9 months ago

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

Stockman824
Stockman824 Nov. 14 at 3:40 PM
$PEPG why won’t my Schwab account allow me to buy PEPG? It’s said I have to call Schwab? Is this a temporary thing? Thanks
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 5:43 PM
HC Wainwright & Co. has adjusted their stance on PepGen ( $PEPG ), setting the rating to Buy with a target price of 18 → 20.
0 · Reply
d_risk
d_risk Nov. 12 at 4:36 PM
$PEPG - PepGen Inc. Common Stock - 10Q - Updated Risk Factors PEPG’s risk factors now detail ongoing losses, a strategic pivot to PGN-EDODM1, and winding down DMD R&D, with high funding needs and persistent going concern doubts. Expanded disclosures highlight clinical trial, regulatory, and commercialization hurdles, new risks from social media, patient enrollment, and third-party reliance, plus heightened exposure to litigation, compliance, cybersecurity, and tax uncertainties. IP risks are streamlined but emphasize patent validity and competition. Recent capital raise noted, but volatility, insider control, and no dividends remain key investor risks. #Biotechnology #IntellectualProperty #FundingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/PEPG/10-Q/2025-11-12
0 · Reply
PiratesKingLuffy
PiratesKingLuffy Nov. 12 at 3:10 AM
AMZE Expecting a big move here tomorrow. Very bullish close today!! AMZE has extended its partnership with Adobe Express, expanding platform access to creators in India — a market with over 2 million monetized creators and $350B in consumer spending. The integration lets users design and sell custom merchandise directly on Amaze, streamlining the path from creation to commerce. The expansion follows Amaze’s showcase at Adobe MAX 2025. Lets bank on AMZE such a gem here! $FGL $FIGS $RLMD $PEPG ..1
2 · Reply
RadioIsotope25
RadioIsotope25 Nov. 9 at 2:39 PM
$RADX Jones Trading reaffirms $30 target after the radiopharmaceutical leader - Lantheus invests more ahead of high potential clinical pipeline updates across imaging and radionuclide lutetium therapeutics utilizing same warheads as the blockbuster Pluvicto and Lutathera. $QURE $PEPG $ATNF $RANI
0 · Reply
Daamdoom1711
Daamdoom1711 Oct. 29 at 1:49 PM
$PEPG P O S
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 27 at 6:57 PM
What do $PEPG $IFRX $EYPT have in common? All are owned by Suvretta, Adage, and RA Capital. All have done secondary offering in last several months PEPG at $3.30 and EYPT at $12.50 (both offering last 2 months). All had major short interest increase just prior to offering. PEPG short grew 359% 9.9% float EYPT up 275% current 14% float IFRX up 113% 3% float* $IFRX data due in 0-7 days *They are about to run the play again.
1 · Reply
notreload_ai
notreload_ai Oct. 27 at 3:53 PM
$PEPG , $DYN
0 · Reply
Davidwxyz
Davidwxyz Oct. 27 at 2:14 PM
$PEPG moving up to 7 or 8
2 · Reply
Lowlow1
Lowlow1 Oct. 27 at 12:43 PM
$PEPG ydkg is going to pop at its 52 low rising looking good,.,....just take a look.,...,...,...........hurry upz...
0 · Reply
FetchDog
FetchDog Oct. 27 at 9:24 AM
$PEPG Up in premarket, apparently in sympathy with the buy out of $RNA by Novartis
0 · Reply
TalkMarkets
TalkMarkets Oct. 21 at 9:34 PM
The Right Way To Own Small Cap Stocks $GS $TXN $NVDA $RTX $PEPG https://talkmarkets.com/content/stocks--equities/the-right-way-to-own-small-cap-stocks?post=529649
0 · Reply
Anonymous10000
Anonymous10000 Oct. 19 at 9:06 PM
$PEPG if you want some excitement, check out $SLS tomorrow. Nice AH gain is the start of a run leading into the company announcement Oct. 29. Possible short squeeze!
0 · Reply
Parnell8
Parnell8 Oct. 14 at 5:56 PM
$PEPG 10:1 r/ r is great. If they really solved splice number pt are all way too low, $50 is possible
1 · Reply
optionsReasy
optionsReasy Oct. 13 at 5:22 PM
$PEPG 💩💩💩💩
0 · Reply
GoNoles2012
GoNoles2012 Oct. 10 at 3:17 PM
$PEPG I’m out. Too scared that it’ll free fall back to 2 or 3 dollars
0 · Reply
optionsReasy
optionsReasy Oct. 10 at 11:55 AM
$PEPG today is the day we pump and break out on the PR this weekend. Hopefully…
1 · Reply
DreamCreator
DreamCreator Oct. 9 at 11:02 PM
Keep a close watch on CMCT! $AMBA $CHWY $INDP $PEPG 22
0 · Reply
boomshiva
boomshiva Oct. 9 at 11:39 AM
$PEPG Look out for a buying opp at the open. Bank of America PT raised to $3 (lol) and maintained Underperform rating.
1 · Reply
optionsReasy
optionsReasy Oct. 8 at 4:30 PM
$PEPG pumping so hard rn
0 · Reply
Jefcud
Jefcud Oct. 8 at 4:29 PM
$PEPG
0 · Reply
optionsReasy
optionsReasy Oct. 8 at 2:02 PM
$PEPG 💩
0 · Reply